Nanovibronix Inc (NAOV)

$0.73

-0.03

(-3.36%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $0.73
    $0.76
    $0.73
    downward going graph

    0.68%

    Downside

    Day's Volatility :4.98%

    Upside

    4.33%

    downward going graph
  • $0.67
    $4.23
    $0.73
    downward going graph

    8.42%

    Downside

    52 Weeks Volatility :84.2%

    Upside

    82.74%

    downward going graph

Returns

PeriodNanovibronix IncIndex (Russel 2000)
3 Months
0.03%
0.0%
6 Months
-17.55%
0.0%
1 Year
-76.85%
0.0%
3 Years
-98.03%
-19.9%

Highlights

Market Capitalization
2.0M
Book Value
$1.26
Earnings Per Share (EPS)
-1.68
PEG Ratio
0.0
Wall Street Target Price
10.5
Profit Margin
-112.35%
Operating Margin TTM
-61.67%
Return On Assets TTM
-29.3%
Return On Equity TTM
-112.21%
Revenue TTM
2.9M
Revenue Per Share TTM
1.45
Quarterly Revenue Growth YOY
160.20000000000002%
Gross Profit TTM
167.0K
EBITDA
-2.6M
Diluted Eps TTM
-1.68
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Nanovibronix Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1338.36%

Current $0.73
Target $10.50

Company Financials

FY18Y/Y Change
Revenue
318.0K
↑ 33.05%
Net Income
-4.2M
↓ 16.33%
Net Profit Margin
-1.3K%
↑ 771.12%
FY19Y/Y Change
Revenue
530.0K
↑ 66.67%
Net Income
-5.8M
↑ 39.48%
Net Profit Margin
-1.1K%
↑ 213.08%
FY20Y/Y Change
Revenue
623.0K
↑ 17.55%
Net Income
-4.3M
↓ 25.34%
Net Profit Margin
-694.38%
↑ 398.83%
FY21Y/Y Change
Revenue
1.7M
↑ 172.07%
Net Income
-14.3M
↑ 230.14%
Net Profit Margin
-842.6%
↓ 148.22%
FY22Y/Y Change
Revenue
752.0K
↓ 55.63%
Net Income
-5.4M
↓ 61.85%
Net Profit Margin
-724.47%
↑ 118.13%
FY23Y/Y Change
Revenue
2.3M
↑ 203.59%
Net Income
-3.7M
↓ 31.88%
Net Profit Margin
-162.55%
↑ 561.92%
Q4 FY22Q/Q Change
Revenue
-102.0K
↓ 205.15%
Net Income
-2.1M
↑ 115.6%
Net Profit Margin
2.0K%
↑ 3003.17%
Q1 FY23Q/Q Change
Revenue
-102.0K
↑ 0.0%
Net Income
-2.1M
↑ 0.0%
Net Profit Margin
2.0K%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
294.0K
↓ 388.24%
Net Income
-1.1M
↓ 47.84%
Net Profit Margin
-365.31%
↓ 2383.94%
Q3 FY23Q/Q Change
Revenue
458.0K
↑ 55.78%
Net Income
-727.0K
↓ 32.31%
Net Profit Margin
-158.73%
↑ 206.58%
Q4 FY23Q/Q Change
Revenue
1.2M
↑ 156.99%
Net Income
-813.0K
↑ 11.83%
Net Profit Margin
-69.07%
↑ 89.66%
Q1 FY24Q/Q Change
Revenue
1.2M
↑ 0.0%
Net Income
-813.0K
↑ 0.0%
Net Profit Margin
-69.07%
↑ 0.0%
FY18Y/Y Change
Total Assets
1.6M
↓ 67.52%
Total Liabilities
1.1M
↓ 9.26%
FY19Y/Y Change
Total Assets
2.0M
↑ 28.86%
Total Liabilities
688.0K
↓ 38.41%
FY20Y/Y Change
Total Assets
8.2M
↑ 304.17%
Total Liabilities
5.8M
↑ 748.11%
FY21Y/Y Change
Total Assets
8.6M
↑ 4.78%
Total Liabilities
2.3M
↓ 60.43%
FY22Y/Y Change
Total Assets
5.9M
↓ 31.81%
Total Liabilities
2.6M
↑ 14.6%
FY23Y/Y Change
Total Assets
6.7M
↑ 13.52%
Total Liabilities
2.7M
↑ 1.51%
Q4 FY22Q/Q Change
Total Assets
5.9M
↑ 12.84%
Total Liabilities
2.6M
↑ 28.7%
Q1 FY23Q/Q Change
Total Assets
5.9M
↑ 0.0%
Total Liabilities
2.6M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
3.8M
↓ 34.84%
Total Liabilities
2.7M
↑ 0.76%
Q3 FY23Q/Q Change
Total Assets
7.4M
↑ 92.14%
Total Liabilities
2.7M
↑ 0.19%
Q4 FY23Q/Q Change
Total Assets
6.7M
↓ 9.33%
Total Liabilities
2.7M
↑ 0.56%
Q1 FY24Q/Q Change
Total Assets
6.7M
↑ 0.0%
Total Liabilities
2.7M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-3.6M
↑ 62.69%
Investing Cash Flow
-8.0K
↑ 0.0%
Financing Cash Flow
94.0K
↓ 98.54%
FY19Y/Y Change
Operating Cash Flow
-3.9M
↑ 9.13%
Investing Cash Flow
-2.0K
↓ 75.0%
Financing Cash Flow
4.3M
↑ 4491.49%
FY20Y/Y Change
Operating Cash Flow
-3.4M
↓ 12.47%
Investing Cash Flow
-2.0K
↑ 0.0%
Financing Cash Flow
9.5M
↑ 120.62%
FY21Y/Y Change
Operating Cash Flow
-4.4M
↑ 28.78%
Investing Cash Flow
-3.0K
↑ 50.0%
Financing Cash Flow
4.6M
↓ 51.9%
FY22Y/Y Change
Operating Cash Flow
-7.0M
↑ 61.09%
Investing Cash Flow
-3.0K
↑ 0.0%
Financing Cash Flow
2.1M
↓ 54.32%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.3M
↓ 32.23%
Investing Cash Flow
1000.0
↓ 150.0%
Financing Cash Flow
2.1M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.3M
↑ 0.0%
Investing Cash Flow
-1000.0
↓ 200.0%
Financing Cash Flow
2.1M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Nanovibronix Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nanovibronix Inc
Nanovibronix Inc
-0.64%
-17.55%
-76.85%
-98.03%
-98.79%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-3.46%
20.0%
-4.76%
-20.06%
21.53%
Stryker Corporation
Stryker Corporation
0.78%
11.04%
17.54%
29.67%
60.01%
Boston Scientific Corp.
Boston Scientific Corp.
2.45%
31.16%
50.64%
78.74%
83.32%
Abbott Laboratories
Abbott Laboratories
-1.31%
-6.18%
-9.34%
-13.05%
17.3%
Medtronic Plc
Medtronic Plc
-2.02%
-6.28%
-10.55%
-38.0%
-22.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nanovibronix Inc
Nanovibronix Inc
NA
NA
0.0
0.0
-1.12
-0.29
NA
1.26
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.93
37.93
5.19
2.76
0.21
0.12
NA
11.82
Stryker Corporation
Stryker Corporation
39.04
39.04
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
65.18
65.18
1.8
2.33
0.09
0.05
NA
13.56
Abbott Laboratories
Abbott Laboratories
32.72
32.72
5.99
4.65
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.73
28.73
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nanovibronix Inc
Nanovibronix Inc
Buy
$2.0M
-98.79%
NA
-112.35%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$53.0B
21.53%
37.93
23.01%
Stryker Corporation
Stryker Corporation
Buy
$130.4B
60.01%
39.04
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.0B
83.32%
65.18
12.05%
Abbott Laboratories
Abbott Laboratories
Buy
$180.4B
17.3%
32.72
13.65%
Medtronic Plc
Medtronic Plc
Buy
$101.7B
-22.41%
28.73
11.36%

Insights on Nanovibronix Inc

  • Increasing Revenue

    Revenue is up for the last 5 quarters, -102.0K → 1.17M (in $), with an average increase of 57.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -727.0K → -813.0K (in $), with an average decrease of 5.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 50.6% return, outperforming this stock by 127.4%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 78.1% return, outperforming this stock by 176.7%

Institutional Holdings

  • Armistice Capital, LLC

    9.01%
  • Renaissance Technologies Corp

    1.40%
  • Vanguard Group Inc

    1.08%
  • Geode Capital Management, LLC

    0.52%
  • AmTrust Financial Services Inc

    0.45%
  • Tower Research Capital LLC

    0.22%

Company Information

nanovibronix inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology. the company's patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. this unique development may be utilized for a variety of medical requiring low cost therapeutic ultrasound applications. the company's patch based product diagnosis, painshield®, carries an fda clearance. nanovibronix catheter based products include the cathbottm . nanovibronix inc. is located in elmsford, ny. its subsidiary, nanovibronix ltd. is located in nesher, israel.

Organization
Nanovibronix Inc
Employees
10
CEO
Mr. Brian M. Murphy
Industry
Health Technology

FAQs